

2/26/04

Form PTO 1449		
ATTY DOCKET NO. 89-99	SERIAL NO. 09/731,242	FILING DATE December 6, 2000
APPLICANT Kranz et al.		GROUP 1636

U.S. PATENT DOCUMENTS

Exmr Initial	Document Number	Date (dd-mm-yyyy)	Name	Class	Subclass	Filing Date if Appropriate
	6,300,065	09-10-2001	Kieck, et al.	435	6	

FOREIGN PATENT DOCUMENTS

Document Number	Date	Country	Class	Subclass	Translation Yes/No
WO 99/36369	22-07-1999	PCT			

OTHER PRIOR ART (including Author, Title, Date, Pertinent Pages, etc.)

92		Al-Ramadi BK, et al., (1995) Lack of strict correlation of functional sensitization with the apparent affinity of MHC/peptide complexes for the TCR. <i>J. Immunol.</i> 155: 662-673.
87		Bellio M, et al., (1994), The V β complementarity determining region 1 of a major histocompatibility complex (MHC) class I-restricted T cell receptor is involved in the recognition of peptide/MHC I and superantigen/MHC complex. <i>J. Exp. Med.</i> 179: 1087-1089.
87		Bird, RE, et al., (1988), Single-chain antigen-binding proteins. <i>Science.</i> 242: 423-426
91		Boder, E.T., et al., (2000), Yeast surface display for directed evolution of protein expression, affinity, and stability. <i>Methods Enzymol</i> 328, 430-444.
92		Brodnicki, TC., (1996), Reactivity and epitope mapping of single-chain T cell receptors with monoclonal antibodies. <i>Mol. Immunol.</i> 33:253-263
92		Cho, BK, et al., (1995), Characterization of a single-chain antibody to the β -chain of the T cell receptor. <i>J. Biol. Chem.</i> 270: 25819-25826.
97		Cochran, et al., (2000), A diverse set of oligomeric class II MHC-peptide complexes for probing T-cell receptor interactions. <i>Chemistry & Biology</i> , Vol. 7:683-696.
92		Corr M, et al., (1994), T cell receptor-MHC class I peptide interactions: affinity, kinetics, and specificity. <i>Science</i> 265: 946-949.
92		Engel I, et al., (1988), Site-directed mutations in the VDJ junctional region of a T cell receptor β chain cause changes in antigenic peptide recognition. <i>Cell</i> 54: 473-484.
92		Holler, Phillip D., et al., (2001), CD8- T Cell Transfectants that Express a High Affinity T Cell Receptor Exhibit Enhanced Peptide-dependent Activation. <i>J. Exp. Med.</i> 194: 1043-1052.

EXAMINER <i>David Mays</i>	DATE CONSIDERED 5/11/04
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Form PTO 1449		
ATTY DOCKET NO. 89-99	SERIAL NO. 09/731242	FILING DATE December 6, 2000
APPLICANT Kranz et al.		GROUP 1636

07		Holler, et al., (2002) TCRs with high affinity for foreign pMHC show self-reactivity. <i>Nature Immunology</i> . Published online 9 December 2002; doi:10.1038/nr863
07		Holler, et al., (2003) Quantitative Analysis of the Contribution of TCR/pepMHC Affinity and CD8 to T Cell Activation, <i>Immunity</i> , 18:255-264.
07		Holler, et al., (2000) <i>In vitro</i> evolution of a T cell receptor with high affinity for peptide/MHC, <i>PNAS</i> , 97:5387-5392.
07		Hoogenboom, Hennie R., (1997) Designing and optimizing library selection strategies for generating high-affinity antibodies, <i>Tibtech</i> , 15:62-70.
02		Kasibhatla S. et al., (1993) Simultaneous involvement of all six predicted antigen binding loops of the T cell receptor in recognition of the MHC/antigenic peptide complex. <i>J. Immunol.</i> 151:3140-51.
07		Kieck, M.C., et al., (2001), High affinity T cell receptors from yeast display libraries block T cell activation by superantigens. <i>J Mol Biol</i> 307:1305-1315.
07		Malchiodi EL, (1995), Superantigen binding to a T cell receptor β chain of known three-dimensional structure. <i>J. Exp. Med.</i> 182:1833-1845.
07		Shusta, E.V., et al., (2000), Directed evolution of a stable scaffold for T-cell receptor engineering. <i>Nat Biotechnol</i> 18:754-759.
07		Wittrup, K.D., (2000), The single cell as a microplate well. <i>Nat Biotechnol</i> 18:1039-1040.
02		Yoon, ST., (1994), Both high and low avidity antibodies to the T cell receptor can have agonist or antagonist activity. <i>Immunity</i> 1:563-569.

EXAMINER <i>David Sings</i>	DATE CONSIDERED <i>5/1/04</i>
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	